Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Recommendations from the GBMHM and the Fi-LMC for the diagnosis and management of chronic myeloid leukemia].

Bulletin du cancer - 1 Apr 2026

Cayuela Jean-Michel, Dulucq Stéphanie, Hayette Sandrine, Millot Frédéric, Nibourel Olivier, Nicolini Franck-Emmanuel, Raimbault Anna, Sloma Ivan, Réa Delphine

Abstract excerpt

Molecular biologists play an important role in therapeutic decisions in the context of Chronic Myelogenous Leukemia (CML). Before treatment, it is mandatory to identify the BCR::ABL1 fusion and any prognostic cytogenetic abnormalities that may be present. During treatment, regular assessment of measurable residual disease (MRD) is essential to objectively evaluate the optimal response and identify situations of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Resistance, Neoplasm
Share to France

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Fusion Proteins, bcr-abl

Share to ABL1 gene

Share to Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Share to Mutation

Share to Neoplasm, Residual

Share to Protein Kinase Inhibitors

Source

Identifiers

PMID: 40908230
DOI: 10.1016/j.bulcan.2025.05.017

Genes

ABL1
BCR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Recommendations from the GBMHM and the Fi-LMC for the diagnosis and management of chronic myeloid leukemia].PMID 40908230Read ↗

Best Practices in Chronic Myeloid Leukemia Monitoring and Management.Semantic proximity Read ↗

Treatment and molecular monitoring update in chronic myeloid leukemia management.Semantic proximity Read ↗

[Molecular monitoring: an essential component of the treatment for chronic myeloid leukemia].Semantic proximity Read ↗

Evaluating treatment response of chronic myeloid leukemia: emerging science and technology.Semantic proximity Read ↗

A review of the European LeukemiaNet recommendations for the management of CML.Semantic proximity Read ↗

[Diagnosis and Therapy of Acute Myeloid Leukemia].Semantic proximity Read ↗

Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet.Semantic proximity Read ↗

Laboratory tools for diagnosis and monitoring response in patients with chronic myeloid leukemia.Semantic proximity Read ↗

Present and future of molecular monitoring in chronic myeloid leukaemia.Semantic proximity Read ↗

Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upSemantic proximity Read ↗

Molecular monitoring of chronic myeloid leukemia: present and future.Semantic proximity Read ↗

Chronic Myeloid Leukemia, Version 1.2019, NCCN Clinical Practice Guidelines in OncologySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.